EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2

Rui Shu, Song Tian, Weiyi Qu, Jinjie Yang, Wei Shi, Xinyan Li, Toujun Zou, Changjin Jiang, Yuxuan Zhang, Zifeng Yang, Han Tian, Hailong Yang und 4 weitere

Journal of Lipid Research · 2025

DOI: 10.1016/j.jlr.2025.100835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2025. Verfasst von Rui Shu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan, China. Hauptthemen laut MEDLINE: Imidazoles, Perilipin-2, Fatty Liver, Protective Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Major Science and Technology Projects of China, Science Fund for Distinguished Young Scholars of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatohepatitis (MASH) has become a global health challenge with limited therapeutic strategy. Here, this study aims to identify promising drug candidates for MASH and clarify its pharmacological mechanism. By extensive screening of FDA-approved hepatoprotective medicines using a PA/OA-stimulated hepatocytes model, we identified daclatasvir showing potent anti-MASH capacity against hepatic steatosis deposition and inflammatory response. The hepatoprotective benefits of daclatasvir were further validated in MASH mouse models, induced by a high-fat high-cholesterol (HFHC) diet for 16 weeks or a methionine-choline-deficient (MCD) diet for 4 weeks, as supported by markedly improved histopathological characteristics, serum biochemical level, and transcriptomic analyses. Using the molecular docking assay followed by isothermal titration calorimetry confirmation, we identified that daclatasvir functions as a new perilipin-2 (PLIN2) inhibitor by interrupting its stability. In specific, PLIN2 subjected to MARCH6-mediated protein degradation in a K11-type ubiquitination. Daclatasvir can directly bind to PLIN2 and enhance its interaction with MARCH6, leading to markedly strengthened PLIN2 ubiquitinational degradation and the subsequent decline in lipid droplet disintegration and lipotoxicity. The specific mutation at the binding amino acid sites of PLIN2 with daclatasvir largely abolished the anti-MASH benefit of daclatasvir. In conclusion, the findings of our study for the first time identified the anti-HCV drug daclatasvir as a novel and potent PLIN2 protein degradant for protection against MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesPerilipin-2Fatty LiverProtective AgentsNon-alcoholic Fatty Liver DiseaseCarbamatesAnimalsValinePyrrolidinesMiceHumansMaleDrug Evaluation, PreclinicalMice, Inbred C57BLHepatocytesMolecular Docking Simulation

Stichwörter der Autor:innen

MASHPLIN2daclatasvirprotein degradationubiquitination

Substanzen

daclatasvirCarbamatesValinePyrrolidinesImidazolesPerilipin-2Protective Agents

Autor:innen und Institutionen

  • Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan, China.
  • Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan, China; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medici…
  • Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan, China; Qujing Medical College Basic Medical Department, Qujing, China.
  • State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Ganzhou, China; School of Pharmacy, Gannan Medical University, Ganz…
  • Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.

Förderung

  • National Natural Science Foundation of China
  • National Major Science and Technology Projects of China
  • Science Fund for Distinguished Young Scholars of Hubei Province

Zitieren

APA

Shu, R., Tian, S., Qu, W., Yang, J., Shi, W., Li, X., Zou, T., Jiang, C., Zhang, Y., Yang, Z., Tian, H., Yang, H., Fu, J., She, Z. G., Li, H., & Zhang, X. J. (2025). Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2025.100835

Vancouver

Shu R, Tian S, Qu W, Yang J, Shi W, Li X, et al. Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2. Journal of Lipid Research. 2025. doi:10.1016/j.jlr.2025.100835

BibTeX
@article{Shu2025,
  author = {Shu, Rui and Tian, Song and Qu, Weiyi and Yang, Jinjie and Shi, Wei and Li, Xinyan and Zou, Toujun and Jiang, Changjin and Zhang, Yuxuan and Yang, Zifeng and Tian, Han and Yang, Hailong and Fu, Jiajun and She, Zhi-Gang and Li, Hongliang and Zhang, Xiao-Jing},
  title = {Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2},
  journal = {Journal of Lipid Research},
  year = {2025},
  doi = {10.1016/j.jlr.2025.100835}
}
Kostenlos starten →